BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Prognosis
9044 results:

  • 1. Dual‑regulated oncolytic adenovirus carrying
    Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
    Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
    Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
    Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CircAGFG1 Promotes Ovarian cancer Progression Through the miR-409-3 p/ZEB1 Axis.
    Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
    Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identification of necroptosis-related gene signatures for predicting the prognosis of ovarian cancer.
    Qin Y; Sheng Y; Ren M; Hou Z; Xiao L; Chen R
    Sci Rep; 2024 May; 14(1):11133. PubMed ID: 38750159
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [The clinicopathological features of adult thyroid tumors with DICER1 mutation].
    Tang J; Huang JJ; Luo YL; Zhang LK; Wang QQ; Chen J; Liu ZY
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1623-1627. PubMed ID: 38742350
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Effect of chemotherapy on prognosis in patients with primary pancreatic signet ring cell carcinoma: A large real-world study based on machine learning.
    Huang K; Yuan X; Zhao P; He Y
    PLoS One; 2024; 19(5):e0302685. PubMed ID: 38739633
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
    Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
    BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Columnar Cell Thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary Thyroid Carcinoma and Follicular Neoplasms.
    Higgins KE; Sadow PM; Johnson DN; Wang P; Wanjari P; Cipriani NA
    Head Neck Pathol; 2024 May; 18(1):39. PubMed ID: 38727854
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study.
    Poiraud C; Lenne X; Bruandet A; Theis D; Bertrand N; Turpin A; Truant S; El Amrani M
    World J Surg Oncol; 2024 May; 22(1):123. PubMed ID: 38711136
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
    Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
    World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian cancer.
    Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
    Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.
    Tanemura M; Furukawa K; Mikamori M; Asaoka T; Yasuoka H; Marukawa D; Urata Y; Yamada D; Kobayashi S; Eguchi H
    Sci Rep; 2024 May; 14(1):10199. PubMed ID: 38702437
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
    Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
    Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Pituitary abscess: a descriptive analysis of a series of 19 patients-a multi-center experience.
    Xue Q; Shi X; Fu X; Yin Y; Zhou H; Liu S; Sun Q; Meng J; Bian L; Tan H; He H
    Eur J Med Res; 2024 May; 29(1):262. PubMed ID: 38698484
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian cancer.
    Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
    In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Targeting KRAS in pancreatic cancer.
    Stickler S; Rath B; Hamilton G
    Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
    Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
    World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Identification and validation of an anoikis-related genes signature for prognostic implication in papillary thyroid cancer.
    Zhao R; Lu Y; Wan Z; Qiao P; Yang L; Zhang Y; Huang S; Chen X
    Aging (Albany NY); 2024 Apr; 16(8):7405-7425. PubMed ID: 38663918
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 453.